Journal of Materials Science: Materials in Medicine

, Volume 21, Issue 2, pp 551–556

Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma

Article

DOI: 10.1007/s10856-009-3925-8

Cite this article as:
Liu, P., Li, Z., Zhu, M. et al. J Mater Sci: Mater Med (2010) 21: 551. doi:10.1007/s10856-009-3925-8

Abstract

This study aims to determine the sensitivity, specificity and accuracy of epidermal growth factor receptor monoclonal antibody (EGFRmAb) modified poly(lactic acid-co-l-lysine) nanoparticles (PLA-PLL-EGFRmAb) NPs delivery system to EGFR positive cancer cells. In the study, a new PLA-PLL-EGFRmAb NPs was prepared. The cellular cytotoxicity, cellular uptake, and the targeted effect for hepatocellular carcinoma of PLA-PLL-EGFRmAb NPs were investigated. In vitro, the findings of Flow cytometry and Confocal Laser scanning Biological Microscopy showed that PLA-PLL-EGFRmAb NPs can bind to hepatocellular carcinoma cells and were uptaken effectively. In vivo in the SMMC-7721 xenograft mouse model, PLA-PLL-EGFRmAb NPs could target to the tumor effectively, which demonstrated a better targeting. These results showed that the PLA-PLL-EGFRmAb NPs have the potential to be used as a target delivery carrier for tumor therapies.

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.State Key Lab for Modification of Chemical Fibers and Polymer Materials, College of Materials Science and EngineeringDonghua UniversityShanghaiPeople’s Republic of China
  2. 2.National Laboratory for Oncogenes and Related GenesCancer Institute of Shanghai Jiao Tong UniversityShanghaiPeople’s Republic of China
  3. 3.Cancer Institute of Shanghai Jiao Tong UniversityShanghaiPeople’s Republic of China

Personalised recommendations